Guo Qinglong

                Publisher:基礎醫學Release time:2017-12-26Times of browsing:205

                Qinglong Guo

                Name

                Qinglong Guo

                Technical title

                Professor; Doctoral Supervisor

                Job Titles

                Dean of The School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University


                Director of Jiangsu Key Laboratory of Carcinogenesis and Intervention


                Director of Technology Platform of Preclinical Pharmacodynamic Evaluation for New Anti-Tumor Drugs, National Ministry of Science and Technolog

                Major

                Tumor Pharmacology, Development of Natural Anticancer Drug, and Target discovering

                Research Awards

                2016 the second prize of National Science and Technology Progress Award (3rd)


                2015 the first prize of Science and Technology Progress Award of the Ministry of Education (2nd)


                2015 the first prize of science and technology of Jiangsu Province (2nd)

                2007 the second prize of science and technology progress of Jiangsu Province Award (2nd)

                Talent Awards

                2014 Jiangsu Province Young and Middle-aged Experts with Outstanding Contributions

                2013 " 333 high - level talents training project " Young chief scientist in Jiangsu


                2008 " 333 high - level talents training project " Young and middle-aged leading talent in Jiangsu

                2007 University " Blue Project " young academic leaders in Jiangsu


                2006 Six talents peak ( Class A ) - funded project in Jiangsu Province

                2006 Jiangsu Province Outstanding Educators

                Major

                research

                interests

                Prof. Guo is mainly engaged in the tumor pathogenesis and nature antitumor drug discovery research. His mainly studies are foucued on the below aspacts:

                • Based on the etiology and pathogenesis of cancer stem cells in cancer, study the different signals between cancer stem cell and normal stem cell growth and differentiation; clarify the regulation target protein and exact molecular mechanism and search for drug candidates targeting cancer stem cells;

                • Study the effectiveness, targets and mechanism of nature cancer drugs involving in angiogenesis, tumor metastasis, signal transduction and cell apoptosis; and provide the oretical basis for clinical cancer therapy;

                • Reveal the structure and function of the tumor signal transduction pathways and network, and search for the potential new targets of anti-tumor drugs through the application of chemical biology research means.

                Achievement

                • More than 170 papers published in SCI research papers with the total number of citations reaching more than 4500 times. The paper about the mechanism of Wogomoside, a independent research and development of new anti-tumor drug, published in April 2013 in the international hematology authoritative magazine “BLOOD”, IF was 10.55.The discovery of new foundations in oncology was published in the "Cell Death and Differentiation” which was published by the Nature Publishing Group in 2011 and ranked as "the 100 most influential international papers in China in 2012".


                • Presided over more than 30 topics funded by National  Natural  Science  Foundation  of China, Ministry of Science and Technology of China and the provincial ministry, with a total funding of more than 45 million yuan.


                • Presided over the completion of  four first class national new drugs with national independent intellectual property and one candidate compound, of which three have obtained clinical research papers, two are still being studied. Successfully assigned three independently developed first class national new drugs with national independent intellectual property with a total transfer fund of nearly 50 million yuan.


                • Applied for 24 national invention patents and granted 20 patents.

                Representative Publications

                1、Yan Chen, Hui Hui, Hao Yang, Kai Zhao, Yansu Qin, Cong Gu, Xiaotang Wang, Na Lu, and Qinglong Guo*. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells. Blood. 2013 May 2;121(18):3682-91 (IF10.558)

                2、Lei Qiang, Tian Wu, Hai-Wei Zhang, Na Lu, Rong Hu, Ya-Jing Wang, Li Zhao, Fei-Hong Chen, Xiao-Tang Wang, Qi-Dong You, Qing-Long Guo*. HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death and Differentiation. 2012;19(2):284-94. (IF8.849)

                3、Yue Zhao, Qinglong Guo, Kai Zhao, Yuxin Zhou, Wenjun Li, Chuyue Pan, Lei Qiang, Zhiyu Li, Na Lu*. Small molecule GL-V9 protects against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy. OncoImmunology. 2017 Dec. (IF7.45)

                4、Kai Zhao, Yuxin Zhou, Chen Qiao, Ting Ni, Zhiyu Li, Xiaotang Wang, Qinglong Guo, Na Lu*, Libin Wei*. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells. Journal of Hematology & Oncology. 2015 Apr 23;8:41 (IF 6.3)

                5、Xiaobo Zhang, Yue Kang, Tongxin Huo, Ran Tao , Wang X, Zhiyu Li, Qinglong Guo*, Li Zhao*. GL-V9 induced upregulation and mitochondrial localization of NAG-1 associates with ROS generation and cell death in hepatocellular carcinoma cells. Free Radic Biol Med. 2017, 112:49-59

                5、Lin Yang, Yinan Yuan, Chengyu Fu, Xuefen Xu, Jieying Zhou, Shuhao Wang, Lingyi Kong, Zhiyu Li, Qinglong Guo*, Libin Wei*. LZ-106, a novel analog of enoxacin, inducing apoptosis via activation of ROS-dependent DNA damage response in NSCLCs. Free Radical Biology and Medicine. 2016 Jun;95:155-68. (IF 5.736)

                6、Li Zhao, Wei Li, Yuxin Zhou, Yi Zhang, Shaoliang Huang, Xuefen Xu, Zhiyu Li  and Qinglong Guo*.  The overexpression and nuclear translocation of Trx-1 during hypoxia confers HepG2 cells resistance to DDP and GL-V9 reverses the resistance by suppressing Trx-1/Ref-1 axis. Free radical biology & medicine, 2015.82 :p.29-41 (IF 5.736)

                7、Libin Wei, Yuxin Zhou, Chen Qiao, Ting Ni, Zhiyu Li,  Qidong You*, Qinglong Guo* , Na Lu*. Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization. Cell Death & Disease.2015. Apr 9;6:e1714 (IF 5.133)

                8、Yang Sun, Yue Zhao, Jing Yao, Li Zhao, Zhaoqiu Wu, Yu Wang, Di Pan, Hanchi Miao, Qinglong Guo*, Na Lu* Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation. Biochemical  Pharmacology 2015 Mar 15;94(2):142-54. (IF 5.009)

                9、Hui Li, Hui Hui, Jingyan Xu, Hao Yang, Xiaoxiao Zhang, Xiao Liu, Yuxin Zhou, Zhiyu Li, Qinglong Guo*, and Na Lu*.Wogonoside Induces Growth Inhibition and Cell Cycle Arrest via Promoting the Expression and Binding Activity of GATA-1 in Chronic Myelogenous Leukemia Cells. Archives of Toxicology. 2015 Jun 24, pp 1-16 (IF 5.98)

                Address

                Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Tong Jiaxiang 24, Nanjing 21009, P.R.C

                Phn

                86-25-83271055;

                Fax

                86-25-83271055

                E-mail

                qinglongguo@hotmail.com



                videos6中国农村妞